Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06402357 | High Intensity Focused Ultrasound in Prostate Cancer | PHASE2 | RECRUITING | 25 | — | — | May 14, 2025 | Aug 1, 2029 | Jun 15, 2025 | 1 | United States |
Evaluate the in-field failure-free survival (IFFFS) of localized radiorecurrent prostate cancer patients receiving focal HIFU treatment at 12 months. IFFFS is defined as the absence of biopsy proven clinically significant prostate cancer in the treated zone.
| Arm | Type | Description |
|---|---|---|
| High Intensity Focused Ultrasound | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Focal One high intensity focused ultrasound device | DEVICE | Participants will be treated with one session of high intensity focused ultrasound using the Focal One device. |
Inclusion Criteria: * Patient has elected to undergo focal high intensity focused ultrasound therapy for radiorecurrent prostate cancer * Males who are ≥ 18 years of age * Eastern Cooperative Oncology Group Performance Status of 0-3 * A history of prostate cancer treated with radiation therapy +/- ...